A Study to Evaluate Safety and Efficacy of AMZ002 Treatment, Compared With Vigabatrin in Participants With Infantile Spasms

Withdrawn before enrolling · Phase 3

Conditions studied: Spasms, Infantile

In brief

The main purpose of this study is to evaluate the efficacy of AMZ002 compared to Vigabatrin in participants with newly diagnosed infantile spasms (IS).

Key facts

Study ID

NCT05128344

Run by

Amzell

People needed

0

Starts

2023-04-01

Expected to finish

2025-12-01

Last updated by the study team

2023-04-20

Who can join

Age: 0 and older, up to 2. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participant has been diagnosed with IS within 6 weeks prior to Screening. Diagnostic criteria include both clinical spasms and an EEG pattern consistent with hypsarrhythmia or significant abnormality compatible with IS
• Participant has normal renal function as defined by an estimated glomerular filtration rate (eGFR) greater than [>] 60 milliliter/minute (mL/min)/1.73 m\^2, calculated as eGFR = 0.413 × (height [Centimeter (cm)]/serum creatinine [milligrams per deciliter {mg/dL}])
• Participant's legally authorized representative (that is [i.e.], parent or guardian) must provide written informed consent obtained per Institutional Review Board (IRB) policy and requirements, consistent with the International Council for Harmonisation (ICH)
• Participant's parent/guardian is able to understand and willing to comply with study procedures and restrictions

You may not qualify if…

• Participant has been diagnosed with tuberous sclerosis
• Participant has acute illness considered clinically significant by the Investigator within 30 days prior to Screening
• Participant has a diagnosis of recent systemic fungal infection; history of ocular herpes simplex; history of or current peptic ulcer; uncontrolled hypertension or congestive heart failure; or any other condition that would be significantly impacted by the study drug
• Participant has a preplanned surgery or procedure(s) that would interfere with the conduct of the study
• Participant has received any prior treatment for IS
• Participant has been previously treated with adrenocorticotropic hormone (ACTH), corticosteroids, or Vigabatrin for seizures;
• Participant has been previously treated with a course of corticosteroids for an indication other than seizures within 30 days prior to Screening
• Participant has a known or suspected allergy to ACTH or Vigabatrin or any component of AMZ002 or Vigabatrin
• Participant has used any other investigational drug within 30 days or 5 half-lives prior to the first dose of AMZ002 or Vigabatrin (whichever is longer)
• Participant' s parent/guardian is unable to provide written informed consent and/or to complete the daily diary
• Participant has any other disease, condition, or therapy that, in the opinion of the Investigator, might compromise safety or compliance, preclude the participant from successfully completing the study, or interfere with the interpretation of the results

Where it is running

• The Childrens Hospital Colorado — Aurora, Colorado, United States
• Miami Children's Hospital — Miami, Florida, United States
• Advent Health Orlando — Orlando, Florida, United States
• Arnold Palmer Hospital For Children — Orlando, Florida, United States
• Childrens Healthcare of Atlanta — Atlanta, Georgia, United States
• Ann and Robert H. Lurie Children's Hospital of Chicago — Chicago, Illinois, United States
• University of Kentucky Hospital — Lexington, Kentucky, United States
• Children's Brain Institute — Lexington, Massachusetts, United States
• Children's Hospital of Michigan — Detroit, Michigan, United States
• Staten Island University Hospital, North — Staten Island, New York, United States
• Wake Forest Baptist Medical Center - PPDS — Winston-Salem, North Carolina, United States
• UT Southwestern Medical Center — Dallas, Texas, United States
• Fundacion para la Lucha contra las Enfermedades Neurologicas de la Infancia — Buenos Aires, Argentina
• Hospital Italiano de Buenos Aires — Buenos Aires, Argentina
• Paediatric Hospital Dr. Juan P. Garrahan — Buenos Aires, Argentina
• CHU Bordeaux - Hopital des Enfants — Bordeaux, France
• HFME-Hospices Civils de Lyon — Bron, France
• Hopital Roger Salengro - CHU de Lille — Lille, France
• Hopital Necker - Enfants Malades — Paris, France
• Hopital de Hautepierre — Strasbourg, France
• Indira Gandhi Institute of Child Health — Bangalore, Karnataka, India
• Amrita Advanced Centre for Epilepsy — Kochi, Kerala, India
• Bharati Vidyapeeth Deemed University - Bharati Hospital — Pune, Maharashtra, India
• All India Institute of Medical Sciences — New Delhi, National Capital Territory of Delhi, India
• Azienda Ospedaliero Universitaria — Ancona, Italy

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.